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Abstract
Background: The prevalence of significant obstructive coronary artery disease with complex lesions is high in
patients who have low extremity artery disease (LEAD). However, intermediate- or long-term cardiovascular
prognosis of LEAD patients undergoing percutaneous transluminal angioplasty (PTA) remains poor. Accordingly,
prophylactic coronary revascularization may modify short- and long-term cardiovascular outcomes of LEAD patients
receiving PTA. Because myocardial ischemic symptoms are often masked in LEAD and the accuracy of non-invasive
stress tests is usually limited, a high-quality randomized controlled trial aimed at the investigation of the prognostic
role of coronary evaluation strategies before PTA is warranted.
Methods/Design: The proposed study is designed as a prospective, multi-center, open-label, superiority,
randomized controlled trial. The study is conducted in high-volume centers for PTA and coronary revascularization
in Taiwan. To meet the inclusion criteria, the patients must be at least 20 years old, have known LEAD, and have
been admitted for elective PTA. We plan to enroll 450 participants who are randomly allocated to a routine group
(routine coronary angiography without a previous non-invasive stress test before PTA) and a selective group
(selective coronary angiography based on the results of non-invasive stress tests before PTA) with 1:1 ratio. Besides,
we expect to enroll about 250 additional participants, who are not willing to be randomly assigned, in the
registration group. The choice of revascularization procedure depends on the operator’s or cardiovascular team’s
suggestion and the patient’s decision. Clinical follow-up will be performed 30 days after PTA and every 6 months
until the end of the 1-year follow-up for the last randomly assigned participant. The primary endpoint is the
composite major adverse cardiac event on long-term follow-up. Pre-specified secondary and other endpoints are
also evaluated. Those assessing biomarkers and clinical endpoints are all blinded after assignment to interventions.
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Discussion: The results of the trial will, for the first time, support better decision-making for coronary evaluation
before PTA in LEAD. If favorable, routine coronary angiography followed by revascularization will improve
cardiovascular outcomes in LEAD patients undergoing PTA.
Trial registration: ClinicalTrials.gov identifier: NCT02169258 (registered on 21 June 2014); registry name: Routine
Coronary Catheterization in Low Extremity Artery Disease Undergoing Percutaneous Transluminal Angioplasty
(PIROUETTE-PTA).
Background
Patients with low extremity artery disease (LEAD) have
a high risk of death from cardiovascular cause [1]. The
existence and severity of coronary atherosclerosis are
known to be correlated to those of peripheral artery dis-
ease [2–5]. The prevalence of significant obstructive cor-
onary artery disease (CAD) is high (up to 70 %) in
patients who have LEAD [2, 6]. Besides, complex coron-
ary artery lesions are more common in patients with
LEAD than in those without [5]. Furthermore, patients
with concomitant LEAD are prone to have a greater
chance of coronary disease progression [7]. Since myo-
cardial infarction is a major cause of peri-operative death
in vascular surgery [6], substantial efforts, such as risk
stratification and routine or selective coronary angiog-
raphy/revascularization before vascular surgery [8–11],
have been made in order to improve cardiovascular out-
come during operation. Despite inconsistent results in
previous clinical studies [12–14], a recently published
prospective randomized controlled trial (RCT) with 208
enrolled cases showed that a strategy of routine coronary
angiography positively impacts long-term outcome of
patients with peripheral artery disease at medium-high
risk for vascular operation [6]. Nevertheless, coronary
angiography/revascularization is recommended only in
some clinical situations before vascular surgery by clin-
ical guidelines [15–17].
Percutaneous transluminal angioplasty (PTA) is usu-
ally the first choice of revascularization for the majority
of patients with LEAD in the current era. However,
intermediate- or long-term prognosis of LEAD patients
undergoing PTA remains poor; the average rate of total
mortality is 25 % and the average rate of cardiovascular
death is 12 % [18–21]. CAD is an independent predictor
of total mortality after PTA [18]. Furthermore, ischemia/
reperfusion injury after PTA can cause systemic inflam-
matory response [22, 23], probably leading to peri-
procedural cardiovascular mortality in the existence of
significant CAD [24]. Interestingly, silent ischemia is
common in patients with LEAD because of the high
prevalence of diabetes mellitus and inactivity in such pa-
tients. A commonly used stress test, the treadmill exer-
cise test, for screening the existence of CAD is usually
unsuitable in patients with LEAD because intermittent
claudication with resultant limited activity or in bedrid-
den status is frequently present due to severe peripheral
artery disease. Furthermore, the accuracy of the available
stress tests, including the treadmill exercise test, dobuta-
mine stress echocardiography (DSE), or dipyridamole
thallium 201 myocardial perfusion scintigraphy (dTS), is
not so high (around 70–75 %), probably hampering vul-
nerable cases from receiving beneficial revascularization
therapy, especially in asymptomatic CAD. Accordingly,
prophylactic coronary revascularization may modify
short- and long-term cardiovascular outcomes of LEAD
patients receiving PTA. However, there is no RCT aimed
at the investigation of the prognostic role of routine
angiography and revascularization before PTA for
LEAD. In addition, it has never been mentioned in the
clinical guidelines. Therefore, there is substantial vari-
ability in practice strategies among interventionists.
Taken together, further investigation of the clinical role
of routine screening for the presence of CAD with sub-
sequent revascularization has strong rationality and is
deemed mandatory in LEAD patients undergoing PTA.
In this principal investigator-initiated prospective RCT,
the PIROUETTE-PTA (Prognostic Impact of Routine
Coronary Catheterization in Low Extremity Artery
Disease Undergoing Percutaneous Transluminal Angio-
plasty) Study investigators will evaluate the prognostic
effects of routine coronary angiography (routine strat-
egy) versus selective coronary angiography based on the
results of non-invasive stress tests (selective strategy) or
conservative management (real-world strategy) before
PTA for LEAD. The potential mechanisms will be eluci-
dated. We hypothesize that a strategy of routine coron-
ary angiography will positively impact long-term
outcome as well as favorable cost-effectiveness, being su-
perior to “selective strategy” or “real-world” strategy, in
LEAD patients receiving PTA.
Methods/Design
Study design
The proposed study is designed as a prospective, multi-
center, open-label, superiority RCT. This study protocol
with amendment (version 5.0; 25 May 2014) has been
Chen et al. Trials  (2016) 17:112 Page 2 of 9
approved by the institutional review board (IRB) of
National Cheng Kung University Hospital (identifier: B-
BR-103-023) and has been registered in ClinicalTrials.-
gov (identifier: NCT02169258). Provisions of all items
from the World Health Organization Trial Registration
Data Set can be found in this protocol and at www.clini-
caltrials.gov. This study conforms to CONSORT (Con-
solidated Standards of Reporting Trials) 2010 guidelines
for RCTs [25] and CONSORT extension for trials asses-
sing non-pharmacologic intervention [26] (Additional
file 1). The study protocol also fulfills SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) 2013 guidelines [27]; Additional file 2 shows this
in more detail. All study participants give informed con-
sent and this study follows the regulation of the ethics
committee of the National Cheng Kung University
Hospital. Any modifications to the protocol will require
a formal amendment approved by the IRB of National
Cheng Kung University Hospital and other participating
sites. The investigators and study nurses will fully ex-
plain the study protocol and get the informed consent
back from potential trial participants or authorized sur-
rogates. An additional signed consent form must be ob-
tained from all participants in sub-studies if information
with respect to sample collection is not covered in the ori-
ginal informed consent form for the main PIROUETTE-
PTA study. The study is conducted in high-volume
centers (either academic medical centers or regional
hospitals) for PTA and coronary revascularization in
Taiwan. Reference to where list of study sites can be ob-
tained at www.clinicaltrials.gov.
Participants and eligibility
This prospective RCT will consecutively enroll about
700 (450 randomly assigned and estimated 250 in regis-
tration strategy) eligible patients (≥20 years old) who
have known LEAD (documented by previous angiog-
raphy or sonography) and were admitted for elective
PTA. The flow diagram is shown in Fig. 1. The definition
of LEAD will be the presence of significant stenosis
(≥70 % narrowing as compared with the reference vessel
size), including total occlusion, in at least one major ar-
tery in the low extremities. Subjects are excluded if they
have at least one of the following situations before
screening: known CAD or unstable angina within the
past 3 months, acute myocardial infarction within the
past 6 months, known CAD having received percutan-
eous coronary intervention (PCI) or bypass surgery
within the past 6 months, plan to do bypass surgery for
known LEAD, pregnancy, documented active malig-
nancy, and need for emergency PTA. The inclusion and
exclusion criteria are listed in Table 1.
Eligibility criteria for investigating centers and those
performing the interventions
The minimal requirements of the investigating centers
are as follows: (1) a medical center or a regional hospital
equipped with at least 500 acute care beds, (2) an
Fig. 1 Participant flow diagram. PTA percutaneous transluminal angioplasy
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experienced participating site where there is a good
track record with respect to conducting clinical trials,
and (3) a high-volume center with at least 500 PCI pro-
cedures and at least 100 PTAs each year. Those who are
performing the interventions should fulfill both of the
following eligibility criteria: (1) an experienced investiga-
tor who has a good track record with respect to con-
ducting clinical trials and (2) an experienced operator
with at least 75 PCI procedures and at least 50 PTAs
each year.
Blinding and randomization
Owing to the nature of the trial interventions, it will not
be possible to blind the investigators at clinical trial sites,
the participants, or the participants’ relatives. All other
parties in the trial will be blinded. Those assessing bio-
markers, single-nucleotide polymorphisms, micro-
ribonucleic acids, and clinical endpoints are all blinded
after assignment to interventions. Investigators conduct-
ing the statistical analyses will be blinded; the two inter-
vention groups and one registry group will be coded as,
for example, A, B, and C.
Eligible participants were randomly assigned to routine
strategy or selective strategy by using unrestricted
randomization and open label for allocation. Sealed en-
velopes for allocation concealment are provided. The al-
location sequence is generated by Ting-Hsing Chao.
Detailed information regarding the allocated group is
given on cards contained in sequentially numbered,
opaque, and sealed envelopes. These are prepared at the
core coordinating center and kept in an appropriate lo-
cation on each site. After enrollment of a participant,
the appropriate numbered envelope is opened at the par-
ticipating site. The information on whether the patient is
to be a “routine” or “selective” case can be found on the
card and this information then is given to the coordin-
ator of the core coordinating center. Then, the investiga-
tor and research nurse follow the intervention protocol
according to the allocation assignment. If participants
are not willing to be randomly assigned, they will be in-
cluded in the registration group if they agree. This infor-
mation should also be given to the coordinator of the
core coordinating center. The enrollment will be closed
if the target number of randomly assigned participants is
reached.
Allocation and intervention
Participants allocated to the systemic strategy will re-
ceive routine coronary angiography before PTA without
a previous non-invasive stress test, and subjects allo-
cated to the selective strategy will undergo non-invasive
evaluation of possible myocardial ischemia by using DSE
or dTS followed by coronary angiography if the test is
obviously positive for ischemia. Clinical decisions are
reached by consensus of operators, patients, and family,
as usual care in the registration group.
Angiographic strategy
CAD is defined as significant luminal narrowing (≥50 %
diameter stenosis as compared with the size of the adja-
cent reference vessel) in at least one of the coronary ar-
teries (left main trunk, left anterior descending artery,
left circumflex artery, and right coronary artery) or their
major branches (diagonal branches, obtuse marginal
branches, acute marginal branches, posterior descending
artery, and posterior lateral branches). Based on the
regulation of Taiwan National Health Insurance, signifi-
cant CAD needing further revascularization is defined as
luminal stenosis of at least 70 % of the major epicardial
vessels and bypass graft vessel or their major branches
(≥50 % for left main trunk or instent restenotic lesion)
with reference vessel larger than 2.5 mm in diameter
and moderate area of vulnerable myocardium for ische-
mia. Intermediate stenotic lesions, luminal stenosis of
around 50 to 70 %, should be determined if they are
hemodynamically significant by fractional flow reserve.
Intermediate lesions with a fractional flow reserve of not
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
1. Must be at least 20 years old. Capable of giving written
informed consent.
1. Known coronary artery disease or unstable angina within the past 3 months.
2. Agrees to comply with the study protocol. 2. Acute myocardial infarction within the past 6 months.
3. Known low extremity artery disease (documented by previous
angiography or sonography) admitted for elective percutaneous
transluminal angioplasty.
3. Known coronary artery disease having received percutaneous coronary
intervention or bypass surgery within the past 6 months.
4. Plans to do bypass surgery for known low extremity artery disease.
5. Has been pregnant.
6. Has documented active malignancy.
7. Needs emergency percutaneous transluminal angioplasty.
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more than 0.8 are considered hemodynamically signifi-
cant and require further revascularization.
Coronary revascularization strategy
The choice of revascularization procedure, either PCI or
coronary artery bypass surgery, depends on the opera-
tor’s or cardiovascular team’s suggestion and the
patient’s decision. A staged approach (myocardial revas-
cularization followed by PTA) and simultaneous ap-
proach (PCI immediately followed by PTA at the same
time if clinically suitable) are both allowed. However,
PTA followed by myocardial revascularization within
21 days after PTA is also allowed in some participating
sites because of local IRB request but should be limited
to specific situations, in which the utmost benefit for pa-
tients is selected by clinical judgment. The duration
from revascularization to PTA should be within 60 days.
PCI is performed at the time of coronary angiography by
using new-generation drug-eluting (more encouraging)
or bare metal stents. Participants were put on dual anti-
platelet treatment, including 100 mg aspirin and 75 mg
clopidogrel per day, thereafter. Aspirin is used indefin-
itely, whereas add-on clopidogrel is used for at least
1 month in bare metal stent placement and 3 months in
drug-eluting stent deployment. The usual practices of in-
terventionists or surgeons with respect to evaluating the
severity of CAD and selecting revascularization strategy
are determined through literature review and through a
survey of study interventionists or surgeons to achieve
consensus. Each study interventionist or surgeon should
agree to adhere to the aforementioned intervention
protocol. All images of coronary angiography and PCI
are recorded. A senior experienced interventionist who
is not aware of assignments of study groups will review
a sufficient number of the off-line images in an attempt
to ensure the adherence of investigators with the proto-
col. There are no relevant concomitant care and inter-
ventions that should be prohibited during the trial.
Blood sampling and measurement of biomarkers
Blood samples are obtained from peripheral arteries in
all study subjects before PTA (20 ml) and after PTA
(10 ml) and are prepared and stored for enzyme-linked
immunosorbent assay as well as genotyping and meas-
urement of micro-ribonucleic acids in plasma and
mononuclear cells.
Data collection and outcome measurement
The minimum follow-up period is 1 year and the max-
imum is 3 years. Clinical outcomes are obtained by chart
review if the patient is still in the hospital and followed
up by clinic visit at 30 days after indexed PTA if the pa-
tient has been discharged from the hospital and every
6 months thereafter. If participants miss indicated clinic
visits, study assistants will call or directly contact the
participants or subjects’ family.
The primary endpoint is the composite major adverse
cardiac event (MACE) on long-term follow-up. Pre-
specified secondary endpoints include the MACE be-
tween the screening and 30 days after PTA, and the
composite major coronary event on long-term follow-
up. Other endpoints include death from any cause, con-
gestive heart failure requiring hospitalization, and any
coronary revascularization. The MACE includes cardio-
vascular death, non-fatal myocardial infarction, non-fatal
stroke, and target vessel revascularization (any un-
planned coronary vessel revascularization). The compos-
ite major coronary event includes fatal or non-fatal
myocardial infarction, recurrent angina pectoris, and tar-
get vessel revascularization (any unplanned coronary
vessel revascularization). The diagnosis of myocardial in-
farction and stroke has been previously described in de-
tail [6]. Clinical follow-up will be performed 30 days
after PTA and every 6 months until the end of the 1-
year follow-up for the last randomly assigned partici-
pant. The follow-up schedule is listed in Table 2. All
outcome data should still be collected for participants
who discontinue or deviate from intervention protocols.
The clear definitions of each component of primary and
pre-specified secondary endpoints are provided to all as-
sessors, and training of assessors to enhance the quality
of measurements is performed on site initiation visit.
The pre-specified endpoints and serious adverse
events (SAEs) should be reported to the data manage-
ment committee and accompanied with required docu-
ments. The primary, secondary, and other endpoints are
adjudicated on the basis of pre-specified criteria by an
endpoint adjudication committee whose members are
not aware of assignments of study groups. A conclusion
is determined and achieved by voting or reaching con-
sensus after discussion from members.
Data management and monitoring
Electronic case report forms (CRFs) for the PIROUETTE-
PTA trial are developed on the infrastructure of the
Clinical Study Information System (CSIS) in cooperation
between the coordinating investigator and a data manager
at the Clinical Research Center of National Cheng Kung
University Hospital. CSIS is the information manage-
ment service provided by the Taiwan Clinical Trial
Bioinformatics and Statistical Center, Training Center,
and Pharmacogenomics Laboratory to facilitate the
coordinating investigator in building up the electronic
CRF system in investigator-initiated trials. This re-
source center is funded by the National Research
Program for Biopharmaceuticals under grant support
by the Ministry of Science and Technology (grant
number 104-2325-B-002-033) and the Center for
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Systems and Synthetic Biology in National Yang-Ming
University in Taiwan. Access to the CSIS will be pos-
sible around the clock every day and data can be en-
tered continuously for all the randomly assigned
patients. The coordinating investigator will have ac-
cess to monitor the data input. If the entry is partially
or completely missing or seems flawed on one or
more randomly assigned patients, the coordinator will
have the opportunity to contact the primary investiga-
tor in order to correct or complement data inputs to
optimize the quality of the data. There are 13 CRFs
to be filled on the CSIS at each indicated visit in the
current study; Additional file 3 shows clinical data to
be collected and recorded in more detail. The steer-
ing committee has access to the full trial dataset.
Original CRFs and source document will be kept on
file and stored in numerical order and in a secure place
with limited access at the participating site. All study-
related records, materials, or documents are identified
only by a coded identification number to keep partici-
pants’ confidentiality, whereas any records that should
contain names or other personal identifiers, such as in-
formed consent forms, will be stored separately from
study records. An inspection team will select participat-
ing sites to monitor quality of the study at audit visits.
Besides, a subset of the original CRFs will be requested
for quality control during study. When a form is se-
lected, the participating site staff will send the copy to
the data management committee for inspection and
double data entry.
We will provide a data and safety monitoring plan ra-
ther than establishing a data and safety monitoring com-
mittee because local IRBs consider that the interventions
performed in the current study are medical routines.
The data and safety monitoring plan includes reporting
SAEs on time, increasing monitoring frequency, and
analyzing safety data every 3 months. An interim ana-
lysis is performed on the primary endpoint by an
independent statistician, who is blinded for the treat-
ment allocation, when 50 % of patients have been ran-
domly assigned and have completed 6-month follow-up.
The statistician will report to the steering committee.
The steering committee makes the final decision to ter-
minate the trial and will report to the IRB of National
Cheng Kung University Hospital. The trial will be ended
by using symmetric stopping boundaries at a P value of
less than 0.001. The trial will not be stopped in case of
futility unless the statistician advises otherwise and the
steering committee decides to terminate the trial for fu-
tility after discussion.
An adverse event that meets the criteria for an SAE
between study enrollment and the end of the study will
be reported to the local IRB. An SAE for this study is
any untoward medical occurrence causing any of the fol-
lowing: a life-threatening condition, severe or permanent
disability, or prolonged hospitalization. An SAE occur-
ring after a participant withdraws consent from the
study will not be reported unless the investigators con-
sider that the event might have been caused by the
protocol procedure. We will continue health care for
trial participants regardless of having potential trial-
related harm.
Strategies to avoid and treat missing data
We have four strategies for limiting missing data in the
conduct of this trial [28]: (1) selecting experienced inves-
tigators who have a good track record with respect to
conducting clinical trials; (2) providing monetary incen-
tives, which meet rigorous ethical requirement, to inves-
tigators and study staff for completeness of data
collection; (3) providing reminder cards conveying the
information that keeping participants in the trial until
the end is important to investigators, study staff, and
participants; and (4) keeping contact with participants.
Missing data will be treated with the multiple imput-
ation method.
Table 2 Follow-up schedule
V0 Cath PCI CABG PTA V1 V2 V3 V4 V5 V6 V7 V8
Time elapse from PTA 0 30 (±7)D 24 (±2)W 48 (±2)W 72 (±2)W 96 (±2)W 120 (±2)W 144 (±2)W 168 (±2)W





BP/HR X X X X X X X X X
History and PE X X X X X X X X X
BCS biochemistry study, BH body height, BP blood pressure, BW body weight, CABG coronary artery bypass grafting, Cath coronary catheterization, CBC complete
blood cell count, CRF case report form, D days, HR heart rate, miRNAs micro-ribonucleic acids, PCI percutaneous coronary intervention, PE physical examination,
PTA percutaneous transluminal angioplasty, SNPs single-nucleotide polymorphisms, V visit, W weeks
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Power estimation and sample size calculation
As previously reported, the CARP (Coronary Artery
Revascularization Prophylaxis) trial [13] shows a mortal-
ity of 23 % in the no-revascularization group, at a me-
dian of 2.7 years after randomization, and an incidence
of MACE can be observed in 20 % of cases within
30 days after major vascular surgery. In addition, our
previous study shows 25 % mortality, 8 % non-fatal myo-
cardial infarction, 2 % non-fatal stroke, and 15 % coron-
ary revascularization at a median of 10 months after
PTA (total MACE rate is 35 %) [18]. Furthermore, a pre-
vious study showed that an absolute risk reduction of
16.7 % in MACE was observed in patients receiving rou-
tine coronary angiography versus selective group before
major vascular surgery [6]. Therefore, we calculated that
we would detect an absolute risk reduction of 16 % (esti-
mated risk reduced from 40 % to 24 %) in primary com-
posite events at long-term follow-up by enrolling a total
sample of 450 patients (sample size of at least 432 with
an estimated dropout rate of 4 %), with a one-sided
alpha of 0.05, a power of 80 %, and a superior margin of
5 %. Although the superior margin is not absolutely ne-
cessary to demonstrate that the routine strategy is super-
ior to the selective strategy, 5 % superior margin is to
conservatively assess whether using the routine strategy
would significantly reduce not only more but also at
least 5 % greater in MACE than the selective strategy.
The sample size would be smaller if there were no setup
of the superior margin. Strategies for achieving adequate
participant enrollment to reach the target sample size
include selecting high-volume centers and intervention-
ists for PTA and providing monetary incentives, which
meet rigorous ethical requirements, to investigators and
study staff for enrollment of participants.
Statistical analysis plan
To compare baseline characteristics between routine
and selective strategy groups as well as the routine strat-
egy group and the registration group, all interval-scaled
variables will be presented as mean ± standard deviation.
Skewed interval-scaled data will be reported as median
(interquartile range). Categorical variables will be pre-
sented as frequency and proportion (percentage). Chi-
squared or Fisher’s exact test will be used for compari-
son of categorical variables between groups, whereas
Mann-Whitney U test or unpaired Student’s t test will
be used for interval-scaled variables as appropriate.
To compare the endpoints between routine and select-
ive strategy groups, each analysis will be performed by
“intention-to-treat” and “per protocol”. Proportional or
Fisher’s exact test will be used for analysis of the propor-
tion of primary, secondary, and other endpoints between
routine and selective strategy groups as appropriate. For
primary endpoint, significantly greater than 5 %
reduction of MACE in the routine strategy group com-
pared with the selective strategy group will be analyzed.
By using the same statistical methods, subgroup analysis
will include comparison of the proportion of endpoints
in subgroups of these two randomized arms, such as pa-
tients with critical limb ischemia (Rutherford classifica-
tion of at least 4), chronic kidney disease (at least stage
3), end-stage renal disease, old age, different genders, to-
bacco smoking, diabetes mellitus, hypertension, hyper-
lipidemia, metabolic syndrome, anemia, bedridden,
hypoalbuminemia, elevated high-sensitivity C-reactive
protein level, and so on. Kaplan-Meier analysis will be
used to study patient survival and event-free status by
using the log-rank test (Cox-Mantel) to ascertain differ-
ences between groups. If more than one endpoint occurs
within the follow-up period for assessing event-free sta-
tus, only the first event will be used in the analysis.
Generalized estimating equation will be used to address
whether and how the clustering by centers. Missing data
will be treated with the multiple imputation method.
Although the main purpose of this study is not to
compare the endpoints between the routine strategy
group and the registration group or between randomized
groups and the registration group, similar analyses as
above will be performed to explore differences among
patients in these groups. For all analyses, a P value of
less than 0.05 is regarded as statistically significant. All
statistical analyses are performed by using IBM SPSS
Statistics 22.0 for Windows (IBM Corporation, Armonk,
NY, USA), but the subgroup analysis is performed by
using SAS software (Version 9.1.3; SAS Institute Inc.,
Cary, NC, USA).
Discussion
The PIROUETTE-PTA study will be the first pro-
spective RCT to determine the effectiveness of rou-
tine coronary angiography before PTA. Owing to the
well-developed PCI technique and the innovation of
excellent devices, contemporary PCI might provide
not only symptom relief but also prognostic benefit
[29]. If favorable, routine coronary angiography
followed by revascularization may be a better coron-
ary evaluation strategy with respect to cardiovascular
outcomes in LEAD patients undergoing PTA.
All manuscripts and abstracts must be approved by
the steering committee before they are submitted.
The results will be disseminated via journal publica-
tion and abstract presentation on scientific confer-
ences regardless of the magnitude or direction of
effect. A summary of the study results will also be
available at ClinicalTrials.gov. The publication plan of
the study results for authorship policy and timeframe
will be discussed and established before the last par-
ticipant is enrolled.
Chen et al. Trials  (2016) 17:112 Page 7 of 9
Trial status
The study is currently open for recruitment.
Additional files
Additional file 1: Checklist of items for reporting trials of non-
pharmacologic treatment. The information addressed in our study
protocol complying with CONSORT extension for trials assessing non-
pharmacologic intervention is provided in this checklist table. CONSORT
Consolidated Standards of Reporting Trials. (PDF 613 kb)
Additional file 2: SPIRIT 2013 Checklist: Recommended Items to
Address in a Clinical Trial Protocol and Related Documents. The
information addressed in our study protocol complying with SPIRIT 2013
is provided in this checklist table. SPIRIT Standard Protocol Items:
Recommendations for Interventional Trials. (PDF 88 kb)
Additional file 3: Case report forms (CRFs) of PIROUETTE-PTA Study. The
file shows clinical data to be collected and recorded in 13 CRFs. PIROU-
ETTE-PTA Prognostic Impact of Routine Coronary Catheterization in Low
Extremity Artery Disease Undergoing Percutaneous Transluminal
Angioplasty. (PDF 834 kb)
Abbreviations
CAD: Coronary artery disease; CONSORT: Consolidated Standards of
Reporting Trials; CRF: Case record form; CSIS: Clinical Study Information
System; DSE: Dobutamine stress echocardiography; dTS: Dipyridamole
thallium 201 myocardial perfusion scintigraphy; IRB: Institutional Review
Board; LEAD: Low extremity artery disease; MACE: Composite major adverse
cardiac event; PCI: Percutaneous coronary intervention; PIROUETTE-
PTA: Prognostic Impact of Routine Coronary Catheterization in Low Extremity
Artery Disease Undergoing Percutaneous Transluminal Angioplasty;
PTA: Percutaneous transluminal angioplasty; RCT: Randomized controlled
trial; SAE: Serious adverse event.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
I-CC participated in the design of the study and the statistical analysis plan,
carried out the inclusion of patients, and drafted the manuscript. C-HL
participated in the design of the study and the statistical analysis plan,
carried out the inclusion of patients, and helped to draft the manuscript. T-
HC conceived the study, participated in its design and coordination
(including financing), carried out the inclusion of patients and the quality
control of the intervention from day to day and follow-up investigation, and
helped to draft the manuscript. W-KT, T-HL, W-JC, J-KL, H-LH, C-YC, C-CL, P-
CH, W-HL, and P-TL participated in the design of the study and the statistical
analysis plan and carried out the inclusion of patients. P-YL participated in
the design of the study and carried out endpoint adjudication. T-KC
participated in the design of the study, the statistical analysis plan, and
statistical analysis. Y-HL and L-MT participated in the design of the study and
the statistical analysis plan and in quality control of the intervention from
day to day and follow-up investigation. S-YT participated in the design of
the study and provided biomechanical measurement equipment and
training in its use. J-JH participated in the design of the study and the
statistical analysis plan. All authors reviewed the manuscript and approved
the final manuscript.
Authors’ information
Principal supervisor and national coordinator: Ting-Hsing Chao, Associate
Professor of the Department of Internal Medicine, National Cheng Kung
University College of Medicine and Hospital. Primary investigator: I-Chih
Chen, MD, Vice Director of the Department of Internal Medicine, Tainan
Municipal Hospital. Principal investigators and co-principal investigators:
Cheng-Han Lee, MD, PhD; Wei-Kung Tseng, MD, PhD; Tsung-Hsien Lin, MD,
PhD; Wen-Jung Chung, MD; Jen-Kwan Li, MD, PhD; Hsuan-Li Huang, MD;
Chun-Yuan Chu, MD; Chih-Chan Lin, MD; Po-Chao Hsu, MD, PhD; Wen-
Huang Lee, MD; Po-Tseng Lee, MD. Co-supervisors: Ping-Yen Liu, MD, PhD
(chairman of the endpoint adjudication committee); Ting-Kuang Chao, MD,
PhD (chairman of the data management committee); Shih-Ya Tseng, MSc.
Co-supervisor: Yi-Heng Li, Professor and Head of the Section of Cardiology,
National Cheng Kung University Hospital; Co-supervisor and chairman of the
steering committee: Liang-Miin Tsai, Professor and Deputy superintendent of
the National Cheng Kung University Hospital. Co-supervisor: Juey-Jen Hwang,
Professor and Head of the Section of Cardiology, National Taiwan University
Hospital.
Acknowledgments
We are grateful for the assistance of all investigators and study nurses in this
investigator-initiated, randomized, clinical, parallel-group, multi-center,
superiority trial.
Finance
This work was supported in part by the Tainan Municipal Hospital Research
Grant (grant number RA14005); a Landmark Project to Promote Innovation
and Competitiveness of Clinical Trials by the Excellent Clinical Trial and
Research Center in National Cheng Kung University Hospital, Ministry of
Health and Welfare, Taiwan (grant numbers MOHW103-TDU-B-211-113002,
MOHW104-TDU-B-211-113002); the National Cheng Kung University and E-
Da University (grant number NCKUEDA10408); and the Ministry of Science
and Technology, Taiwan (grant number 104-2314-B-006-085). The funding
organizations did not have a role in the design or conduct of this study,
collection, management, analysis or interpretation of data, writing of the
report, or the decision to submit the report for publication.
Author details
1Department of Internal Medicine, Tainan Municipal Hospital, Tainan, Taiwan.
2Department of Internal Medicine, National Cheng Kung University College
of Medicine and Hospital, Tainan, Taiwan. 3Division of Cardiology,
Department of Internal Medicine, National Cheng Kung University College of
Medicine and Hospital, No. 138, Sheng-Li Road, North District, Tainan 704,
Taiwan. 4Division of Cardiology, Department of Internal Medicine, E-Da
University College of Medicine and Hospital, Kaohsiung, Taiwan. 5Division of
Cardiology, Department of Internal Medicine, Kaohsiung Medical University
and Hospital, Kaohsiung, Taiwan. 6Division of Cardiology, Department of
Internal Medicine, Chang-Gung Memorial Hospital Kaohsiung, Kaohsiung,
Taiwan. 7Division of Cardiology, Department of Internal Medicine, National
Taiwan University Hospital, Taipei, Taiwan. 8Division of Cardiology,
Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei
Branch, Taipei, Taiwan. 9Department of Otolaryngology, Far Eastern Memorial
Hospital, New Taipei City, Taiwan. 10Division of Public Health and Preventive
Medicine, Department of Medicine, Faculty of Medicine and Dentistry,
University of Alberta, Edmonton, AB, Canada.
Received: 24 September 2015 Accepted: 17 February 2016
References
1. Duran NE, Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, et al.
Mortality over a period of 10 years in patients with peripheral arterial
disease. N Engl J Med. 1992;326:381–6.
2. Duran NE, Duran I, Gürel E, Gündüz S, Göl G, Biteker M, et al. Coronary
artery disease in patients with peripheral artery disease. Heart Lung. 2010;39:
116–20.
3. Rohani M, Jogestrand T, Ekberg M, van der Linden J, Källner G, Jussila R, et
al. Interrelation between the extent of atherosclerosis in the thoracic aorta,
carotid intima-media thickness and the extent of coronary artery disease.
Atherosclerosis. 2005;179:311–6.
4. Lekakis JP, Papamichael C, Papaioannou TG, Stamatelopoulos KS,
Cimponeriu A, Protogerou AD, et al. Intima-media thickness score from
carotid and femoral arteries predicts the extent of coronary artery disease:
intima-media thickness and CAD. Int J Cardiovasc Imaging. 2005;21:495–501.
5. Sukhija R, Yalamanchili K, Aronow WS, et al. Prevalence of left main
coronary artery disease, of three- or four-vessel coronary artery disease, and
of obstructive coronary artery disease in patients with and without
peripheral arterial disease undergoing coronary angiography for suspected
coronary artery disease. Am J Cardiol. 2003;92:304–5.
6. Monaco M, Stassano P, Di Tommaso L, Pepino P, Giordano A, Pinna GB, et al.
Systematic strategy of prophylactic coronary angiography improves long-term
Chen et al. Trials  (2016) 17:112 Page 8 of 9
outcome after major vascular surgery in medium- to high-risk patients: a
prospective, randomized study. J Am Coll Cardiol. 2009;54:989–96.
7. Hussein AA, Uno K, Wolski K, Kapadia S, Schoenhagen P, Tuzcu EM, et al.
Peripheral arterial disease and progression of coronary atherosclerosis.
J Am Coll Cardiol. 2011;57:1220–5.
8. Dávila-Román VG, Waggoner AD, Sicard GA, Geltman EM, Schechtman KB,
Pérez JE, et al. Dobutamine stress echocardiography predicts surgical
outcome in patients with an aortic aneurysm and peripheral vascular
disease. J Am Coll Cardiol. 1993;21:957–63.
9. Wolf YG, Landersberg G, Mosseri M, Schechter D, Anner H, Weissman C,
et al. Preoperative dipyridamole-thallium scanning, selective coronary
revascularization and long-term survival in patients with critical lower limb
ischemia. J Cardiovasc Surg (Torino). 2001;42:89–95.
10. Landesberg G, Mosseri M, Wolf YG, Bocher M, Basevitch A, Rudis E, et al.
Preoperative thallium scanning, selective coronary revascularization, and
long-term survival after major vascular surgery. Circulation. 2003;108:177–83.
11. Landesberg G, Berlatzky Y, Bocher M, Alcalai R, Anner H, Ganon-Rozental T,
et al. A clinical survival score predicts the likelihood to benefit from
preoperative thallium scanning and coronary revascularization before major
vascular surgery. Eur Heart J. 2007;28:533–9.
12. Massie MT, Rohrer MJ, Leppo JA, Cutler BS, et al. Is coronary angiography
necessary for vascular surgery patients who have positive results of
dipyridamole thallium scans? J Vasc Surg. 1997;25:975–82.
13. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al.
Coronary-artery revascularization before elective major vascular surgery. N
Engl J Med. 2004;351:2795–804.
14. Schouten O, van Kuijk JP, Flu WJ, Winkel TA, Welten GM, Boersma E, et al.
Long-term outcome of prophylactic coronary revascularization in cardiac
high-risk patients undergoing major vascular surgery (from the randomized
DECREASE-V Pilot Study). Am J Cardiol. 2009;103:897–901.
15. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE,
et al. ACCF/AHA focused update on perioperative beta blockade
incorporated into the ACC/AHA 2007 guidelines on perioperative
cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol.
2009;54:e13–118.
16. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP,
et al. ESC Guidelines on the diagnosis and treatment of peripheral artery
diseases: Document covering atherosclerotic disease of extracranial carotid
and vertebral, mesenteric, renal, upper and lower extremity arteries: the
Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of
the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851–906.
17. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al.
ACCF/AHA Focused Update of the Guideline for the Management of
Patients With Peripheral Artery Disease (updating the 2005 guideline): a
report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:
2020–45.
18. Chen IC, Chao TH, Fang CC, Wu IH, Yu CL, Lam CY. Prognostic determinants
of intermediate-term outcome in patients with peripheral artery disease
undergoing percutaneous transluminal angioplasty in southern Taiwan—a
single operator’s experience. Acta Cardiol Sin. 2013;29 Suppl:58.
19. Abularrage CJ, Conrad MF, Hackney LA, Paruchuri V, Crawford RS, Kwolek CJ,
et al. Long-term outcomes of diabetic patients undergoing endovascular
infrainguinal interventions. J Vasc Surg. 2010;52:314–22.e1-4.
20. Chen IC, Yu CC, Wu YH, Chao TH. Elevated neutrophil-to-lymphocyte ratio
predicts intermediate-term outcomes in patients who have advanced
chronic kidney disease with peripheral artery disease receiving
percutaneous transluminal angioplasty. Acta Cardiol Sin. (in press)
21. Huang HL, Chou HH, Wu TY, Chang SH, Tsai YJ, Hung SS, et al. Endovascular
intervention in Taiwanese patients with critical limb ischemia: patient
outcomes in 333 consecutive limb procedures with a 3-year follow-up.
J Formos Med Assoc. 2014;113:688–95.
22. Parmar JH, Aslam M, Standfield NJ, et al. Percutaneous transluminal
angioplasty of lower limb arteries causes a systemic inflammatory response.
Ann Vasc Surg. 2009;23:569–76.
23. Yassin MM, Harkin DW, Barros D'Sa AA, Halliday MI, Rowlands BJ, et al.
Lower limb ischemia-reperfusion injury triggers a systemic inflammatory
response and multiple organ dysfunction. World J Surg. 2002;26:115–21.
24. Yassin MM, Barros D’Sa AA, Parks G, Abdulkadir AS, Halliday I, Rowlands BJ,
et al. Mortality following lower limb ischemia-reperfusion: a systemic
inflammatory response? World J Surg. 1996;20:961–6.
25. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ,
et al. CONSORT 2010 explanation and elaboration: updated guidelines for
reporting parallel group randomised trials. BMJ. 2010;340:c869.
26. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group.
Extending the CONSORT statement to randomized trials of
nonpharmacologic treatment: explanation and elaboration. Ann Intern Med.
2008;148:295–309.
27. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
trials. BMJ. 2013;346, e7586.
28. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al.
The prevention and treatment of missing data in clinical trials.
N Engl J Med. 2012;367:1355–60.
29. Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM,
Galatius S, et al. Effects of cobalt-chromium everolimus eluting stents or
bare metal stent on fatal and non-fatal cardiovascular events: patient level
meta-analysis. BMJ. 2014;349:g6427.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. Trials  (2016) 17:112 Page 9 of 9
